Back to news

Thomas H. Glocer to Retire From Merck Board of Directors in May 2027; Douglas M. Baker, Jr. Appointed Independent Lead Director

Business Wire•18/11/2026•06:45 ET
0

Key Highlights

  • ➤Thomas H. Glocer to retire from Merck board at May 2027 annual meeting
  • ➤Douglas M. Baker Jr. appointed independent lead director effective Jan. 1, 2027
  • ➤Baker has served on Merck’s board since 2022

Expert Statements

Rob Davis, Chairman and chief executive officer of Merck

“Merck has counted on Tom’s expertise and counsel as a trusted voice in our boardroom for many years, and I have relied on him as a valued collaborator. His contributions to our Company have been invaluable, and on behalf of everyone at Merck, I thank him for his dedicated service”

Rob Davis, Chairman and chief executive officer of Merck

“As we look ahead, Doug is a thoughtful, experienced and accomplished leader who will undoubtedly serve the Board well in this expanded role. I look forward to our continued work together as we deliver value to our stakeholders.”

Thomas H. Glocer to Retire From Merck Board of Directors in May 2027; Douglas M. Baker, Jr. Appointed Independent Lead Director

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Thomas H. Glocer intends to retire from the Merck Board of Directors at the Company’s Annual Meeting of Shareholders in May 2027. The independent members of the Board have appointed Douglas M. Baker, Jr., as independent lead director, effective Jan. 1, 2027, succeeding Mr. Glocer in the role.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in